CD8A and neoplasm: For example, inhibiting the CASP9 signaling pathway can help tumor cells recognize their own mtDNA, efficiently secrete IFN-I after radiotherapy, promote the cross-presentation of DCs, and enhance the anti-tumor immunity mediated by CD8+ T cells [166].